Dr Jackie Hunter to become CEO of BBSRC

Will take up the post on 21 October

Dr Jackie Hunter has been named as the new Chief Executive and Deputy Chair of the UK’s Biotechnology and Biological Sciences Research Council (BBSRC).

Hunter is currently Chief Executive of OI Pharma Partners. From 1989–2010 she worked for GlaxoSmithKline and its predecessor companies and was at Astra (now AstraZeneca) earlier in her career. She was made CBE in 2010 for services to the pharmaceutical industry.

‘The BBSRC plays a vital role in shaping and underpinning the diverse and exciting science base that is essential to maintain the international reputation of UK bioscience and biotechnology,’ said Hunter. ‘The potential of this research, and the BBSRC investments in innovation, to support the UK’s growing bioeconomy and socio-economic challenges is huge. I am looking forward to working with the wealth of talent within BBSRC, the research community and its many partner organisations to drive forward UK bioscience.’

The appointment is for four years. Hunter will succeed Professor Douglas Kell.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Subscribe now